Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.

Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN; Immune Tolerance Network Group..

J Allergy Clin Immunol. 2007 Sep;120(3):688-95. Epub 2007 Jul 12.

PMID:
17631952
2.

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y; Immune Tolerance Network Group..

J Allergy Clin Immunol. 2006 Jan;117(1):134-40. Epub 2005 Dec 2.

PMID:
16387596
3.

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB.

J Allergy Clin Immunol. 2004 Feb;113(2):297-302.

PMID:
14767445
4.

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G; Omalizumab Seasonal Allergic Rhinitis Trail Group..

JAMA. 2001 Dec 19;286(23):2956-67.

PMID:
11743836
5.

A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation.

Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H.

Clin Exp Allergy. 2008 Aug;38(8):1290-301. doi: 10.1111/j.1365-2222.2008.03020.x. Epub 2008 May 28.

PMID:
18510696
6.

The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.

Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E.

BioDrugs. 2007;21(6):403-10. Review.

PMID:
18020623
7.

Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.

Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, Della Cioppa G, Gupta N.

Allergy Asthma Proc. 2003 Sep-Oct;24(5):323-9.

PMID:
14619332
8.

Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?

Verbruggen K, Van Cauwenberge P, Bachert C.

Int Arch Allergy Immunol. 2009;148(2):87-98. doi: 10.1159/000155739. Epub 2008 Sep 18. Review.

9.

Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.

Chaker AM, Shamji MH, Dumitru FA, Calderon MA, Scadding GW, Makatsori M, Jones I, He QA, Subramanian KK, Arm JP, Durham SR, Schmidt-Weber CB.

J Allergy Clin Immunol. 2016 Feb;137(2):452-461.e9. doi: 10.1016/j.jaci.2015.08.046. Epub 2015 Oct 31.

PMID:
26531865
10.

Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab).

Kopp MV, Mayatepek E, Engels E, Brauburger J, Riedinger F, Ihorst G, Wahn U, Kuehr J.

Pediatr Allergy Immunol. 2003 Oct;14(5):401-4.

PMID:
14641611
11.

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.

Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U.

J Allergy Clin Immunol. 2002 Feb;109(2):274-80.

PMID:
11842297
12.

Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.

Corren J, Diaz-Sanchez D, Saxon A, Deniz Y, Reimann J, Sinclair D, Davancaze T, Adelman D.

Ann Allergy Asthma Immunol. 2004 Sep;93(3):243-8.

PMID:
15478383
13.

The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.

Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA, Larché M, Durham SR, Francis JN.

J Immunol Methods. 2006 Dec 20;317(1-2):71-9. Epub 2006 Oct 5.

14.

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, Jacobson MR, Kimber I, Till SJ, Durham SR.

J Allergy Clin Immunol. 2011 Feb;127(2):509-516.e1-5. doi: 10.1016/j.jaci.2010.12.1080.

PMID:
21281875
15.

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.

Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U; DUAL study group..

Clin Exp Allergy. 2009 Feb;39(2):271-9. doi: 10.1111/j.1365-2222.2008.03121.x. Epub 2008 Oct 30.

PMID:
19016798
16.

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.

Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, Zielen S, Bez, Friedrichs F, Von Berg A, Gerhold K, Hamelmann E, Hultsch, Kuehr J.

J Allergy Clin Immunol. 2002 Nov;110(5):728-35.

PMID:
12417881
17.

Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.

Casale TB; Prous Science..

Drugs Today (Barc). 2004 Apr;40(4):367-76. Review.

PMID:
15190389
18.

Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules.

Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V.

Clin Exp Allergy. 2010 Sep;40(9):1346-52. doi: 10.1111/j.1365-2222.2010.03548.x. Epub 2010 Jun 28.

PMID:
20604801
19.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
20.

Role of immunmodulators in allergen-specific immunotherapy.

Kopp MV.

Allergy. 2011 Jun;66(6):792-7. doi: 10.1111/j.1398-9995.2011.02553.x. Epub 2011 Feb 18. Review.

Supplemental Content

Support Center